Role of biomarkers in community-acquired pneumonia management

Abstract

Community-acquired pneumonia (CAP) poses a significant global health threat, particularly affecting vulnerable populations. Biomarkers and scoring systems play a crucial role in diagnosing, assessing severity, and guiding treatment decisions for CAP patients. Biomarkers like C reactive protein, procalcitonin, and the neutrophil-to-lymphocyte ratio aid in diagnosis and severity assessment, while scoring systems such as CURB-65 and Pneumonia Severity Index classify patients into risk categories. Emerging biomarkers (uremia, elevated respiratory rate, hypotension, and age ≥ 65) like serum amyloid A and S100 proteins show promise in predicting disease severity and prognosis. However, further research is needed to determine their precise roles and clinical utility in CAP management.

Keywords

CURB-65 / Community-acquired pneumonia / Procalcitonin / Alpha-1 antitrypsin / Serum amyloid A

References

[1] Mani CS, Murray DL. Acute pneumonia and its complications. In: Principles and practice of pediatric infectious diseases. Elsevier; 2012, p. 235-245.e4. DOI: 10.1016/B978-1-4377-2702-9.00034-9.

[2] Kolbaş F, Akça H, Algın A, Özdemir S, Eroğlu S. Pneumonia with systemic lupus erythematous. Eurasian J Crit Care 2020; 2(2): 203-206.

[3] Özkan A, Özdemir S, Altunok İ. Etiology of recurrent pneumonia in a patient with history of malignancy. Phnx Med J 2023; 5(3): 245-246. DOI: 10.38175/phnx.1296699.

[4] Davis D, Thadhani J, Choudhary V, Nausheem R, Vallejo—Zambrano CR, Arifuddin BM, et al. Advancements in the management of severe community—acquired pneumonia: A comprehensive narrative review. Cureus 2023; 15(10): e46893. DOI: 10.7759/cureus.46893.

[5] Restrepo MI, Reyes LF, Anzueto A. Complication of community—acquired pneumonia (including cardiac complications). Semin Respir Crit Care Med 2016; 37(6): 897-904. DOI: 10.1055/s-0036-1593754.

[6] Wunderink RG. Community—acquired pneumonia. Infect Dis 2017: 251-257.e1. DOI: 10.1016/B978-0-7020-6285-8.00028-9.

[7] Karakioulaki M, Stolz D. Biomarkers and clinical scoring systems in community—acquired pneumonia. Ann Thorac Med 2019; 14(3): 165-172. DOI: 10.4103/atm.ATM_305_18.

[8] Carlos P, Gomes R, Coelho J, Chaves C, Tuna C, Louro M. CURB—65 and long—term mortality of community—acquired pneumonia: A retrospective study on hospitalized patients. Cureus 2023; 15(3): e36052. DOI: 10.7759/cureus.36052.

[9] Guo Q, Li HY, Song WD, Li M, Chen XK, Liu H, et al. Updating cut—off values of severity scoring systems for community—acquired pneumonia to orchestrate more predictive accuracy. Ann Med 2023; 55(1): 2202414. DOI: 10.1080/07853890.2023.2202414.

[10] Mbata GC, Chukwuka CJ, Onyedum CC, Onwubere BJ. The CURB—65 scoring system in severity assessment of Eastern Nigerian patients with community—acquired pneumonia: A prospective observational study. Prim Care Respir J 2013; 22(2): 175-180. DOI: 10.4104/pcrj.2013.00034.

[11] Akça HŞ, Algın A, Özdemir S, Sevimli H. Comparison of the efficacy of PSI, CURB—65, CALL and BCRSS in predicting prognosis and mortality in COVID—19 patients. J Exp Clin Med 2021; 38(4): 434-439.

[12] Zaki HA, Hamdi Alkahlout B, Shaban E, Mohamed EH, Basharat K, Elsayed WA, et al. The battle of the pneumonia predictors: A comprehensive meta—analysis comparing the pneumonia severity index (PSI) and the CURB—65 score in predicting mortality and the need for ICU support. Cureus 2023; 15(7): e42672. DOI: 10.7759/cureus.42672.

[13] Ozkan A. Deal predictor studies. J Exp Clin Med 2022; 39(2): 595-596. DOI: 10.52142/omujecm.39.2.64.

[14] Seligman R, Ramos—Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Rosa KD. Biomarkers in community—acquired pneumonia: A state—of—the—art review. Clinics (Sao Paulo) 2012; 67(11): 1321-1325. DOI: 10.6061/clinics/2012(11)17.

[15] Ranzani OT, Coelho L, Torres A. Biomarkers in community—acquired pneumonia: Can we do better by using them correctly? J Bras Pneumol 2019; 45(4): e20190189. DOI: 10.1590/1806-3713/e20190189.

[16] Akoglu EU, Özdemir S, Ak R, Ozturk TC. The discriminative power of inflammatory markers in patients with mild—to—moderate acute pancreatitis: Mean platelet volume, neutrophil—lymphocyte ratio, lymphocyte—monocyte ratio, and neutrophil—monocyte product. South Clin Ist Euras 2021; 32(2): 159-164.

[17] Kokulu K, Günaydın YK, Akıllı NB, Köylü R, Sert ET, Köylü Ö, et al. Relationship between the neutrophil—to—lymphocyte ratio in acute pancreatitis and the severity and systemic complications of the disease. Turk J Gastroenterol 2018; 29(6): 684-691. DOI: 10.5152/tjg.2018.17563.

[18] Liu Q, Sun G, Huang L. Association of the NLR, BNP, PCT, CRP, and D—D with the severity of community—acquired pneumonia in older adults. Clin Lab 2023; 69(12). DOI: 10.7754/Clin.Lab.2023.220330.

[19] Tekin A, Wireko FW, Gajic O, Odeyemi YE. The neutrophil/lymphocyte ratio and outcomes in hospitalized patients with community—acquired pneumonia: A retrospective cohort study. Biomedicines 2024; 12(2): 260. DOI: 10.3390/biomedicines12020260.

[20] Özdemir S. Inflammation: Complexity and significance of cellular and molecular responses. J Acute Dis 2024; 13(1): 3-7. DOI: 10.4103/jad.jad_129_23.

[21] Özdemir S, Algin A. Evaluation of the ability of the C—reactive protein—to—albumin ratio to predict short—term mortality in patients with COVID—19. J Clin Med Kaz 2021; 18(6): 35-39. DOI: 10.23950/jcmk/11324.

[22] Sproston NR, Ashworth JJ. Role of C—reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754. DOI: 10.3389/fimmu.2018.00754.

[23] Ozdemir S, Altunok İ. Comparison of the predictive ability of the blood urea nitrogen/albumin, C—reactive protein/albumin, and lactate/albumin ratios for short—term mortality in SARS—CoV—2—infected patients. Avicenna J Med 2023; 13(1): 43-48. DOI: 10.1055/s-0043-1761471.

[24] Coelho LM, Salluh JI, Soares M, Bozza FA, Verdeal JC, Castro—Faria—Neto HC, et al. Patterns of C—reactive protein RATIO response in severe community—acquired pneumonia: A cohort study. Crit Care 2012; 16(2): R53. DOI: 10.1186/cc11291.

[25] Travlos A, Bakakos A, Vlachos KF, Rovin N, Koulouris N, Bakakos P, et al. C—reactive protein as a predictor of survival and length of hospital stay in community—acquired pneumonia. J Pers Med 2022; 12(10): 1710. DOI: 10.3390/jpm12101710.

[26] Lagerström F, Engfeldt P, Holmberg H. C—reactive protein in diagnosis of community—acquired pneumonia in adult patients in primary care. Scand J Infect Dis 2006; 38(11—12): 964-969. DOI: 10.1080/00365540500388826.

[27] Ozdemir S, Akça HŞ, Algın A, Eroglu SE. Can C—reactive protein—to—albumin ratio be a predictor of short—term mortality in community—acquired pneumonia? Ann Clin Anal Med 2021; 12(9): 1043-1048. DOI: 10.4328/ACAM.20576.

[28] Maruna P, Nedelníková K, Gürlich R, Eroglu SE. Physiology and genetics of procalcitonin. Physiol Res 2000; 49(Suppl 1): S57-S61.

[29] Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: A harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159(2): 253-264. DOI: 10.1111/j.1476-5381.2009.00433.x.

[30] Ratageri VH, Panigatti P, Mukherjee A, Das RR, Goyal JP, Bhat JI, et al. Role of procalcitonin in diagnosis of community acquired pneumonia in Children. BMC Pediatr 2022; 22(1): 217. DOI: 10.1186/s12887-022-03286-2.

[31] Keramat F, Ghasemi Basir HR, Abdoli E, Shafiei Aghdam A, Poorolajal J. Association of serum procalcitonin and C—reactive protein levels with CURB—65 criteria among patients with community—acquired pneumonia. Int J Gen Med 2018; 11: 217-223. DOI: 10.2147/IJGM.S165190.

[32] Subedi B, Louzon P, Zappas K, Onyia W, DeBoer K. Impact of pharmacist—led procalcitonin—guided antibiotic therapy in critically ill patients with pneumonia. Hosp Pharm 2020; 55(3): 204-210. DOI: 10.1177/0018578719836643.

[33] Khilnani GC, Tiwari P, Zirpe KG, Chaudhry D, Govil D, Dixit S, et al. Guidelines for the use of procalcitonin for rational use of antibiotics. Indian J Crit Care Med 2022; 26(Suppl 2): S77-S94. DOI: 10.5005/jp-journals-10071-24326.

[34] Schweizer J, Bustamante A, Lapierre—Fétaud V, Faura J, Scherrer N, Gil LA, et al. SAA (serum amyloid A): A novel predictor of stroke—associated infections. Stroke 2020; 51(12): 3523-3530. DOI: 10.1161/STROKEAHA.120.030064.

[35] Sack GH Jr. Serum amyloid A (SAA) proteins. Subcell Biochem 2020; 94: 421-436. DOI: 10.1007/978-3-030-41769-7_17.

[36] Ma C, Li X, Gao X, He Q, Zhuan B, Ji W, et al. Value of serum amyloid protein dynamic changes on evaluating condition and prognosis of patients with viral and mycoplasma community—acquired pneumonia. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2022; 34(6): 592-596. DOI: 10.3760/cma.j.cn121430-20210223-00273.

[37] Stockley RA. Alpha1—antitrypsin review. Clin Chest Med 2014; 35(1): 39-50. DOI: 10.1016/j.ccm.2013.10.001.

[38] McCarthy C, Dunlea DM, Saldova R, Henry M, Meleady P, McElvaney OJ, et al. Glycosylation repurposes alpha—1 antitrypsin for resolution of community—acquired pneumonia. Am J Respir Crit Care Med 2018; 197(10): 1346-1349. DOI: 10.1164/rccm.201709-1954LE.

[39] de Serres F, Blanco I. Role of alpha—1 antitrypsin in human health and disease. J Int Med 2014; 276(4): 311-335. DOI: 10.1111/joim.12239.

[40] Ogan N, Erçin U, İlgar C, Yüksel A, Gülensoy ES, Akpınar EE, et al. Effect of alpha—1 antitrypsin and alpha—1—acid glycoprotein AAT levels on prognosis in COPD exacerbation and COPD—community—acquired pneumonia patients. J Pulmonol Intens Care 2024; 2(1): 11-13. DOI: 10.51271/JOPIC-0026.

[41] Miyazaki T, Fukushima K, Hashiguchi K, Ide S, Kobayashi T, Sawai T, et al. A high α1—antitrypsin/interleukin—10 ratio predicts bacterial pneumonia in adults with community—acquired pneumonia: A prospective cohort study. Pneumonia (Nathan) 2023; 15(1): 16. DOI: 10.1186/s41479-023-00118-4.

[42] Zhou Y, Zha Y, Yang Y, Ma T, Li HL, Liang JY. S100 proteins in cardiovascular diseases. Mol Med 2023; 29(1): 68. DOI: 10.1186/s10020-023-00662-1.

[43] Goswami D, Anuradha U, Angati A, Kumari N, Singh RK. Pharmacological and pathological relevance of s100 proteins in neurological disorders. CNS Neurol Disord Drug Targets 2023; 22(10): 1403-1416. DOI: 10.2174/1871527322666221128160653.

[44] Wang H, Li D, Wang Y, Mao GJ, Lu GZ, Lan QQ, et al. Clinical significance of serum S100 calcium—binding protein A12 concentrations in patients with community—acquired pneumonia. J Int Med Res 2023; 51(8): 3000605231191021. DOI: 10.1177/03000605231191021.

[45] Liu HY, Xiang HX, Xiang Y, Xu Z, Feng CM, Fei J, et al. The associations of serum S100A9 with the severity and prognosis in patients with community—acquired pneumonia: A prospective cohort study. BMC Infect Dis 2021; 21(1): 327. DOI: 10.1186/s12879-021-06020-y.

[46] Zheng L, Fei J, Xu Z, Zhang C, Fei J, Xu Z, et al. Serum S100A8 as an early diagnostic biomarker in patients with community—acquired pneumonia. Res Square 2020. DOI: 10.21203/rs.3.rs-56033/v1.